// App-Quantinova.ai

P315 : High symptom burden and impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a global burden of illness study

Researchers

Presenter

  • Karki, C

Principal Investigators

  • Sharpe, E

  • Hantsbarger, G

  • Lee, K

  • Perovic, M

  • Raven, L

  • Sajak-Szczerba, M

  • Silber, A

  • Yoon, A

  • Tozer, P

Medical Centers

  • Takeda Pharmaceuticals USA- Inc., Global Evidence and Outcomes, Cambridge MA, United States

  • Trinity Partners- LLC, Heath Economics & Outcomes Research, Waltham- MA, United States

  • Takeda Pharmaceuticals USA Inc., Safety and Health Value Statistics, Cambridge- MA, United States

  • Crohn's and Colitis Canada, Research & Patient Programs, Toronto, Canada

  • European Federation of Crohn’s and Ulcerative Colitis Associations, European Federation of Crohn’s and Ulcerative Colitis Associations, Brussels, Belgium

  • Crohn's and Colitis Australia, n/a, Camberwell, Australia

  • an Federation of Crohns and Ulcerative Colitis Associations, Medical Writing, Brussels, Belgium

  • Takeda Pharmaceuticals, Gastroenterology- Japan Medical Office, Tokyo, Japan

  • St Mark’s Hospital and Academic Institute, Fistula Research Unit, London, United Kingdom

Locations

  • United States

  • Canada

  • Belgium

  • Australia

  • Japan

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

  • Gastroenterology (GU)

  • Genetic Disorder

Disease

  • Inflammatory bowel disease

  • Anal fistula

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cross-Sectional

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved